{"entity":{"id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","aka":[],"tldr":"A phase 2 trial of INCB123667 in ovarian cancer, run by Incyte Corporation, now recruiting.","summary":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 2 interventional study registered as NCT07023627 by Incyte Corporation, with 160 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-04-27. Interventions recorded: INCB123667. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07023627","url":"https://clinicaltrials.gov/study/NCT07023627"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["incb123667"],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07023627","phase":"2","setting":"A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)","sponsor":"Incyte Corporation","enrolled":160,"outcomes":[]},"route":"/trials/nct07023627/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}